Member Info for VertizeaSun

Yahoo Finance is showing AVCT volume traded yesterday as 57 million. A typo surely?

Either way I wouldn't worry about Phase 3. When AVA6K is proven successful it might begin to re-write licensing regulations with the FDA's ODD showing the way. And I recall from about 2 years ago our government's Chief Scientific Adviser saying there was an understanding at the top of the main governments that the licensing of new compounds was too cumbersome and bureaucratic.

The FDA obviously don't agree - here's your Orphan DD, and neither do Susquehanna - here's your £55 million quid.

Why? It's more useful than TA.

Ripley....thank you for posting. I don't think it's personal to ask and it's the first thing I asked my sister when she was diagnosed with melanoma 14 months ago. She's in a west country hospital.

What part of the country do think the patient might be living in?

and the hospital?

And just confirm that - M McNulty - Twitter update

#AVCT almost back to where it was at start of week.

Had a great catch up with mgmt during investor roadshow. Nothing new shared, of course - but in my view the CEO oozed confidence.

Whether it's next week or in 4 weeks, the impact of the #AVA6000 P1a RNS could be monumental.

https://twitter.com/MylesMcNulty/status/1593534018884100098

Copied from ADVFN - I think EnergyShares is the originator (thanks) and still very pertinent:

Professor James Spicer
Avacta Scientific Advisory Board and 442 days into the trial.

In a article for BMJ as role model. Published on:
24 Aug 2022.

Makes a comment like this:

If you're working in a small company that's only got one product, sometimes you need partners like us who have a portfolio of interests, who can really give the bad news that a drug isn't going anywhere.
We need to stop it, and that's explicitly an intention of early phase, Phase I trials. One major contribution we can make is to take a drug which is actually not doing what it should, to discontinue its development as soon as possible. Before too many patients are exposed to an ineffective drug, and before too much money is wasted trying to develop it.

hTtps://www.bmj.com/careers/article/professor-james-spicer-professor-of-experimental-cancer-medicine-king-s-college-london

£1.40? Not with current volume. A dozen trades totalling less than 20K in the 30 minutes between 8:15 and 8:45.

Susquehanna disagree.

I guess you're expecting a couple of low-ball offers!

It's not complete crap. It's the most likely explanation for a bunch of spooked sellers. Madness of crowds and all that.

Spooked by Clovis's imminent bankruptcy and its association with FAP.

Indeed but I'm pointing out we are where we are partly because of Baked-In Labour Party stupidity. Define a woman?

So you regret not voting for Jeremy Corbyn?

Confidentiality Advisory Group?

Inviting questions from whom?

Richob .... all true except for Avacta not having spare cash. I believe AS pointed out he would be looking at more acquisitions.

Medica opens next Monday 14th, in Dusseldorf.

https://www.medica-tradefair.com/vis/v1/en/exhibitors/medcom2022.2727408?oid=80396&lang=2&_query=avacta

Avacta Diagnostics, based in Wetherby, UK., utilises its proprietary Affimer® platform to develop high performing diagnostics and works with partners world-wide to develop Affimer reagents with the objective of establishing royalty bearing license deals.
The Affimer® ...
Diagnostic rapid tests

Alastair Smith, CEO Avacta....10 January 2022:

"We believe COVID-19 testing remains a long-term commercial opportunity. We will therefore use the robustness of the Affimer® platform, and what we have learned about the SARS-CoV-2 virus, to generate the next generation antigen test that will be as resilient as possible to any future mutations."

Alex....thanks for the post. Avacta is most certainly ramping up the PR.....now why would they do that!!